Med Oncol:晚期胃癌术后放化疗可行

2012-08-02 朱金 医学论坛网

  《内科肿瘤学》(Med Oncol)杂志近期发表的一项研究表明,晚期胃癌患者接受精准手术(definitive surgery)后接受5-氟尿嘧啶和顺铂化疗继以放化疗是可行的。   虽然在胃癌治疗中取得重大进展,但多数患者行精准手术后复发。先前研究显示,患者术后对5氟尿嘧啶+顺铂治疗继以放化疗耐受性良好。   该研究的目的是要评估上述方案治疗晚期患者的长期疗效并确定切除

  《内科肿瘤学》(Med Oncol)杂志近期发表的一项研究表明,晚期胃癌患者接受精准手术(definitive surgery)后接受5-氟尿嘧啶和顺铂化疗继以放化疗是可行的。

  虽然在胃癌治疗中取得重大进展,但多数患者行精准手术后复发。先前研究显示,患者术后对5氟尿嘧啶+顺铂治疗继以放化疗耐受性良好。

  该研究的目的是要评估上述方案治疗晚期患者的长期疗效并确定切除修复交叉互补基因1(ERCC1)和胸苷酸合成酶(TS)基因表达是否能预测这些患者的临床结局。研究人群包括36例晚期胃癌术后患者,给予其上述方案治疗。在经过中位48.9个月的随访后,患者中位无病生存期为45个月,总生存期 66.4个月。16例患者(44%)无病生存。ERCC1和TS表达模式与至复发时间无显著相关性(分别为P=0.302和P =0.707)。

  相关链接:Sonnenblick A, Rottenberg Y, Kadouri L, Wygoda M, Rivkind A, Vainer GW, Peretz T, Hubert A.Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer.Med Oncol.2012 Jul 8.
 



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1864368, encodeId=c7e518643681d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jun 01 20:48:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809260, encodeId=7bc01809260e8, content=<a href='/topic/show?id=7168832369f' target=_blank style='color:#2F92EE;'>#胃癌术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83236, encryptionId=7168832369f, topicName=胃癌术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Tue Aug 07 11:48:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276565, encodeId=10a512e656507, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Aug 04 01:48:00 CST 2012, time=2012-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287849, encodeId=86e5128e849a6, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Aug 04 01:48:00 CST 2012, time=2012-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605806, encodeId=8b7e160580646, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 04 01:48:00 CST 2012, time=2012-08-04, status=1, ipAttribution=)]
    2013-06-01 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1864368, encodeId=c7e518643681d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jun 01 20:48:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809260, encodeId=7bc01809260e8, content=<a href='/topic/show?id=7168832369f' target=_blank style='color:#2F92EE;'>#胃癌术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83236, encryptionId=7168832369f, topicName=胃癌术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Tue Aug 07 11:48:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276565, encodeId=10a512e656507, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Aug 04 01:48:00 CST 2012, time=2012-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287849, encodeId=86e5128e849a6, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Aug 04 01:48:00 CST 2012, time=2012-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605806, encodeId=8b7e160580646, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 04 01:48:00 CST 2012, time=2012-08-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1864368, encodeId=c7e518643681d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jun 01 20:48:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809260, encodeId=7bc01809260e8, content=<a href='/topic/show?id=7168832369f' target=_blank style='color:#2F92EE;'>#胃癌术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83236, encryptionId=7168832369f, topicName=胃癌术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Tue Aug 07 11:48:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276565, encodeId=10a512e656507, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Aug 04 01:48:00 CST 2012, time=2012-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287849, encodeId=86e5128e849a6, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Aug 04 01:48:00 CST 2012, time=2012-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605806, encodeId=8b7e160580646, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 04 01:48:00 CST 2012, time=2012-08-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1864368, encodeId=c7e518643681d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jun 01 20:48:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809260, encodeId=7bc01809260e8, content=<a href='/topic/show?id=7168832369f' target=_blank style='color:#2F92EE;'>#胃癌术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83236, encryptionId=7168832369f, topicName=胃癌术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Tue Aug 07 11:48:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276565, encodeId=10a512e656507, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Aug 04 01:48:00 CST 2012, time=2012-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287849, encodeId=86e5128e849a6, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Aug 04 01:48:00 CST 2012, time=2012-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605806, encodeId=8b7e160580646, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 04 01:48:00 CST 2012, time=2012-08-04, status=1, ipAttribution=)]
    2012-08-04 yzh399
  5. [GetPortalCommentsPageByObjectIdResponse(id=1864368, encodeId=c7e518643681d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jun 01 20:48:00 CST 2013, time=2013-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809260, encodeId=7bc01809260e8, content=<a href='/topic/show?id=7168832369f' target=_blank style='color:#2F92EE;'>#胃癌术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83236, encryptionId=7168832369f, topicName=胃癌术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Tue Aug 07 11:48:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276565, encodeId=10a512e656507, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Aug 04 01:48:00 CST 2012, time=2012-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287849, encodeId=86e5128e849a6, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57318, encryptionId=4d185e31825, topicName=放化疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Sat Aug 04 01:48:00 CST 2012, time=2012-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605806, encodeId=8b7e160580646, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 04 01:48:00 CST 2012, time=2012-08-04, status=1, ipAttribution=)]

相关资讯

我国专家发现胃癌患者两种蛋白质表达高低有“玄机”

  讯(通讯员蔡心轶 记者程守勤)南京医科大学肿瘤中心周建伟教授带领的课题组在对国内1806例胃癌患者样本分析发现,人体内的代号分别为JWA和XRCC1的两种蛋白质的指标可用来判断中国人群胃癌患者术后的存活状况,并可预测化疗效果。这一成果日前已在美国癌症研究协会的《临床癌症研究》杂志发表。   据参与课题研究的王守宇博士介绍,这两种蛋白质属于DNA修复蛋白。众所周知,DNA分子是遗传物

PLoS One:胃癌预后标记物hsa-miR-335

胃癌(GC)是最常见的恶性肿瘤,在中国癌症患者中是引发死亡的首要原因之一。癌症复发的主要因素是治疗失败和胃癌患者手术切除后5年存活率水平低的主要原因。因此,筛选出能预测复发风险的潜在生物标志物是解决胃癌患者预后的关键问题。 近日,发表于PLoS One杂志上的一则研究证实hsa-miR-335可作为胃癌预后的标记物。研究人员纳入74例胃癌患者进行研究,包括31例复发和43例无复发胃癌患者。首先,

老年胃癌术后营养支持可**肠内营养

  近日,浙江大学医学院附属第一医院、浙江中医药大学附属第二医院普外科的黄国强、于吉人、冯永生等人共同发表论文,旨在探讨老年胃癌患者术后早期肠内营养支持(EN)的可行性、安全性与临床效果及其与肠外营养支持(TPN)的比较。研究指出,肠内营养符合生理状态,可促进机体恢复,减少并发症,且价格低廉,可作为老年胃癌患者术后首选的营养支持方式。 该论文发表于2012年第9期《中国老年学杂志》上。

Clin Cancer Res:胃癌患者术后存活状况的蛋白JWA和XRCC1被发现

  南京医科大学肿瘤中心周建伟教授带领的课题组对国内1806例胃癌患者样本分析后发现,人体内代号分别为JWA和XRCC1的两种蛋白质指标,可用来判断中国胃癌患者术后的存活状况,并可预测化疗效果。该研究论文日前在美国癌症研究协会的《临床癌症研究》杂志上发表。   该研究证实,胃癌组织中JWA和XRCC1表达低的人,癌症恶性程度高,发展快,预后差,但这些病人通常对铂类辅助化疗药物较敏感,疗效较好;J

Anticancer Research:5-FU+顺铂改善晚期胃癌患者预后

     《抗癌研究》(Anticancer Research)杂志近期发表的一项研究提示,5-氟尿嘧啶(5-FU)联合顺铂可改善晚期或复发性胃癌患者预后。   该研究是一项Ⅱ期研究,在26例晚期或复发性胃癌患者中评估了5-FU联合顺铂的效果和安全性。治疗方案包括,连续5天静脉输注顺铂3.3 mg/m2/天,连续4周每隔1天(第1、3、5天)持续静脉输注5-FU 

IDF 2012:Hp感染者Th17细胞增加与消化性溃疡有关

英国诺丁汉大学E Staples、R J M Ingram、K Hussain等人在2012英国消化疾病联盟大会(DDF)上做了幽门螺旋杆菌感染患者Th17细胞数增加可能与消化性溃疡有关的口头报告。幽门螺杆菌(Hp)感染的病人胃黏膜中辅助T细胞17和Tc17细胞数量增加,且IL17,RORC2和IFNG的表达增加。其中IL17表达的增加比IFNG表达明显更高,但IL17的来源还没有得到充分证实。在